Brickell Biotech, Inc.

1.06-0.0300-2.75%Vol 521.82K1Y Perf -1.82%
Apr 9th, 2021 16:00 DELAYED
BID1.05 ASK1.07
Open1.06 Previous Close1.09
Pre-Market- After-Market-
 - -  - -%
Target Price
5.50 
Analyst Rating
— 0.00
Potential %
418.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     50.58
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     50.54
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap70.95M 
Earnings Rating
Price Range Ratio 52W %
27.71 
Earnings Date
12th May 2021

Today's Price Range

1.051.09

52W Range

0.46602.61

5 Year PE Ratio Range

-2.30-1.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.02%
1 Month
-3.64%
3 Months
-0.93%
6 Months
0.95%
1 Year
-1.82%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BBI1.06-0.0300-2.75
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
4.70
5.30
0.01
0.02
-213.10
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-1 147.80
-1 147.30
-521.40
-
RevenueValueIndustryS&P 500US Markets
776.00K
0.01
-41.43
-44.25
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.08-0.15-87.50
Q03 2020-0.17-0.1511.76
Q02 2020--0.43-
Q01 2020--0.45-
Q04 2019--1.38-
Q03 2019--2.27-
Q02 2019-0.77-0.770.00
Q01 2019-1.33-1.47-10.53
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-0.12
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume521.82K
Shares Outstanding66.93M
Trades Count1.16K
Dollar Volume2.76M
Avg. Volume3.66M
Avg. Weekly Volume607.90K
Avg. Monthly Volume1.81M
Avg. Quarterly Volume3.18M

Brickell Biotech, Inc. (NASDAQ: BBI) stock closed at 1.06 per share at the end of the most recent trading day (a -2.75% change compared to the prior day closing price) with a volume of 529.98K shares and market capitalization of 70.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Brickell Biotech, Inc. CEO is Robert Busard Brown.

The one-year performance of Brickell Biotech, Inc. stock is -1.82%, while year-to-date (YTD) performance is 35.81%. BBI stock has a five-year performance of %. Its 52-week range is between 0.466 and 2.61, which gives BBI stock a 52-week price range ratio of 27.71%

Brickell Biotech, Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 97.46, a price to cashflow ratio of 82.40, a PEG ratio of 2.32, a ROA of -78.34%, a ROC of -129.13% and a ROE of -118.22%. The company’s profit margin is -%, its EBITDA margin is -1 147.30%, and its revenue ttm is $776.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Brickell Biotech, Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Brickell Biotech, Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for Brickell Biotech, Inc. is (0), with a target price of $5.5, which is +418.87% compared to the current price. The earnings rating for Brickell Biotech, Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Brickell Biotech, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Brickell Biotech, Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.01, ATR14 : 0.15, CCI20 : -61.32, Chaikin Money Flow : 0.12, MACD : -0.01, Money Flow Index : 30.11, ROC : -12.23, RSI : 47.74, STOCH (14,3) : 42.86, STOCH RSI : 0.53, UO : 55.69, Williams %R : -57.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Brickell Biotech, Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Brickell Biotech, Inc.

Brickell Biotech Inc is a United States-based clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of skin diseases. Its pipeline consists of therapeutics for Hyperhidrosis, Cutaneous T-cell lymphoma, Psoriasis, and Other prevalent severe skin diseases. The company's pipeline products include Sofpironium Bromide, BBI-3000 and BBI-6000 among others.

CEO: Robert Busard Brown

Telephone: +1 720 505-4755

Address: 5777 Central Avenue, Boulder 80301, CO, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

News

Stocktwits